We hypothesize that an AI-guided AF risk stratification approach, particularly when combined with intensified rhythm monitoring using wearable devices and extended ECG patches, will significantly increase AF detection rates compared with standard care. By enabling earlier identification of patients who may benefit from anticoagulation therapy, this strategy has the potential to improve clinical outcomes while minimizing unnecessary exposure to anticoagulant-related bleeding risks. Ultimately, this trial seeks to provide robust clinical evidence supporting the integration of AI-assisted ECG analysis into routine post-stroke care, advancing precision medicine and optimizing resource allocation for patients with ischemic stroke.
18 years or older who are acutely hospitalized due to ischemic stroke;
A 12-lead electrocardiogram upon admission showing sinus rhythm;
Previous diagnosis of atrial fibrillation or flutter;
Diagnosis of atrial fibrillation during hospitalization;
Pre-existing cardiac implantable electronic device (IVD);
Expected inability to attend regular outpatient follow-ups after discharge, or to undergo multiple 14-day ECG recordings;
Parallel
Active Follow-up Group
DeviceHigh-frequency electrocardiogram (ECG) monitoring was conducted, using a smartwatch with continuous photoplethysmography (PPG) monitoring, supplemented by an external single-lead ECG patch for 14 days. Participants recorded ECGs for 14 days immediately after discharge. If the smartwatch detected atrial fibrillation, the patch would be automatically applied for 14 days of recording. After recording, the patch was mailed or delivered in person to the research team for analysis.
Standard Follow-up Group
Other interventionfollowed a standardized follow-up procedure by a neurologist. Each follow-up visit included a medical history and physical examination, without further cardiac-related monitoring. However, if the patient presented with symptoms of arrhythmia, the physician could consult a cardiologist or perform a preliminary 12-lead ECG.
The difference betwee Active Group & Standard Group
The difference between the probability of a new diagnosis of atrial fibrillation or atrial flutter within six months (defined as an atrial fibrillation waveform longer than 30 seconds on a single-lead ECG or a twelve-lead ECG) in subjects identified as high-risk in the AI-assisted group and those who were actively followed up (Group A) and those who were followed up according to standard care (Group D).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
